Naprocur (Naproxen)

Naproxen, the active ingredient in Naprocur, is a nonsteroidal anti‑inflammatory drug (NSAID) presented as an oral dosage form for oral use. It provides relief of mild to moderate pain, reduces inflammation in rheumatoid arthritis and osteoarthritis, eases dysmenorrhea, and lowers fever in adult patients.

GNH USA supplies Naprocur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required.

Naproxen is an NSAID that reduces inflammation and pain by inhibiting cyclooxygenase enzymes.

Mild to moderate pain: provides rapid analgesic relief for common conditions such as tension‑type headaches, dental procedures, and musculoskeletal discomfort associated with strains or sprains. Inflammatory arthritis: decreases joint swelling, stiffness, and functional limitation in chronic conditions like rheumatoid arthritis and osteoarthritis, improving mobility and quality of life. Dysmenorrhea: alleviates menstrual cramps and associated pelvic pain, helping to reduce reliance on additional analgesics during the menstrual cycle. Fever: lowers elevated body temperature in acute febrile episodes, contributing to patient comfort during infections or inflammatory states.

Naproxen may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal upset: nausea, dyspepsia, or abdominal discomfort. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Gastrointestinal ulcer or bleeding: potentially life‑threatening hemorrhage. - Cardiovascular events: increased risk of myocardial infarction or stroke. - Renal impairment: acute kidney injury or worsening chronic kidney disease. - Severe skin reactions: Stevens‑Johnson syndrome, toxic epidermal necrolysis, or drug‑induced hypersensitivity syndrome.

Before initiating naproxen therapy, consider the following precautions to minimize risk.

- Assess renal function: avoid or adjust dose in patients with severe renal impairment. - Evaluate cardiovascular risk: use cautiously in individuals with history of heart disease or stroke. - Review gastrointestinal history: consider gastro‑protective agents for patients with prior ulcers or bleeding. - Avoid in late pregnancy: contraindicated during the third trimester due to fetal risk. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and direct sunlight.

Naproxen can interact with several medicines; awareness of these interactions helps ensure safe use.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may markedly increase bleeding risk. - Selective serotonin reuptake inhibitors (SSRIs): combined use heightens gastrointestinal bleeding potential. - Other NSAIDs or COX‑2 inhibitors: additive toxicity and ulcer risk. - Lithium: naproxen can raise serum lithium concentrations, risking toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: concurrent use may reduce renal perfusion and impair kidney function. - Diuretics: increased risk of renal insufficiency, especially in volume‑depleted patients. - Methotrexate: naproxen may decrease clearance, leading to elevated methotrexate levels and toxicity.